《內房》上海新推七個新盤 每平方米均價全部低於10萬人幣
上海網上房地產官網最新公示一批即將入市的新房項目名單顯示,此次共推出七個項目,分布在浦東、閔行、寶山、嘉定、金山、青浦及臨港等區域,共計房源數961套。該批新房的每平方米均價全部低於10萬元人民幣(下同)。
七個項目中,張江金茂府、古北悅公館及中鐵諾德璟庭均為現房發售。其中,張江金茂府位於浦東康橋,每平方米均價69,019元,共推123套房;古北悅公館位於閔行古北,每平方米均價91,500元,共推99套房;中鐵諾德璟宸位於臨港105板塊,每平方米均價30,000元,共推268套房。
資料顯示,自2025年起,上海累計供應新房達24個批次,總房源數19,560套。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.